Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD38 CAR-T for CD38-positive Hematological Malignancies
NCT05239689Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD38 CAR T-cells in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Incidence of treatment-emergent adverse events at 90 days. Status: unknown.
02
Drugs
CD38 CAR T-cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05239689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239689.